While there are now over 30 FDA-approved selective kinase inhibitors available for the treatment of cancer, the median progression-free survival is still <1 year for a majority of these drugs. Drug resistance is responsible for >90% of deaths in patients with metastatic cancer. In many of these cases, mutations in the target of therapy drive resistance by abolishing or reducing inhibitor affinity while maintaining or increasing kinase activity.